How has your use of B-cell depleting therapy for MS changed during the COVID-19 pandemic?
1 Answer
Mednet MemberInvited Expert
Neurology · Georgetown University
Answered on
There may be no "correct" answer to this question. In my practice, I have not altered my prescribing of B cell therapies. Although we have seen reduced antibody responses in MS patients on B cell therapies, this has not definitively been associated with a significantly increased risk of COVID infect...
Join for free or sign in to see the full answer